{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=67", "query": { "intervention": "SC", "page": 67 }, "page_size": 10 }, "pagination": { "page": 67, "page_size": 10, "total_count": 3867, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=68&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=66&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T08:48:56.851Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07589608", "title": "A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Macupatide", "type": "DRUG" }, { "name": "Eloralintide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 400, "start_date": "2026-05-15", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 40, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07589608" }, { "nct_id": "NCT04607733", "title": "A Study of Mirikizumab in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Mirikizumab Prefilled Syringe", "type": "DRUG" }, { "name": "Mirikizumab Autoinjector", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 240, "start_date": "2020-11-02", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 4, "location_summary": "Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Springfield", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04607733" }, { "nct_id": "NCT06980649", "title": "Study of BHV-1300 in Graves' Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graves Disease" ], "interventions": [ { "name": "BHV-1300", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2025-08-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 10, "location_summary": "South Gate, California • Miami, Florida • Columbus, Georgia + 6 more", "locations": [ { "city": "South Gate", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06980649" }, { "nct_id": "NCT04048135", "title": "A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NASH" ], "interventions": [ { "name": "Pegozafermin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "89bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 101, "start_date": "2019-07-29", "completion_date": "2022-01-19", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 25, "location_summary": "Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more", "locations": [ { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04048135" }, { "nct_id": "NCT06043440", "title": "Down Syndrome Obstructive Sleep Apnea", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Down Syndrome", "Obstructive Sleep Apnea" ], "interventions": [ { "name": "Oxygen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "5 Years to 18 Years" }, "enrollment_count": 230, "start_date": "2023-10-24", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 7, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06043440" }, { "nct_id": "NCT04684368", "title": "A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Nongerminomatous Germ Cell Tumor", "Choriocarcinoma", "Embryonal Carcinoma", "Immature Teratoma", "Malignant Teratoma", "Mixed Germ Cell Tumor", "Pineal Region Germ Cell Tumor", "Pineal Region Immature Teratoma", "Pineal Region Yolk Sac Tumor", "Suprasellar Germ Cell Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Second-Look Surgery", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "3 Years to 29 Years" }, "enrollment_count": 160, "start_date": "2021-07-13", "completion_date": "2029-12-21", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 152, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04684368" }, { "nct_id": "NCT07095452", "title": "A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2026-01-08", "completion_date": "2042-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07095452" }, { "nct_id": "NCT04212091", "title": "Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PGT121.414.LS", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 33, "start_date": "2020-11-10", "completion_date": "2023-01-18", "has_results": true, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 5, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04212091" }, { "nct_id": "NCT03338816", "title": "ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Hepatic Porphyria", "Acute Intermittent Porphyria", "Porphyria, Acute Intermittent", "Acute Porphyria", "Hereditary Coproporphyria (HCP)", "Variegate Porphyria (VP)", "ALA Dehydratase Deficient Porphyria (ADP)" ], "interventions": [ { "name": "Givosiran", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 94, "start_date": "2017-11-16", "completion_date": "2021-05-31", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03338816" }, { "nct_id": "NCT03091673", "title": "Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Glucagon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xeris Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 31, "start_date": "2017-03-27", "completion_date": "2017-09-27", "has_results": true, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-11-06T08:48:56.851Z", "location_count": 7, "location_summary": "Stanford, California • Aurora, Colorado • New Haven, Connecticut + 4 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03091673" } ] }